Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpJournal of Clinical Oncology
• journal#1
Rahul Seth, Hans Messersmith, Varinder Kaur, John M Kirkwood, Ragini Kudchadkar, Jennifer Leigh McQuade, Anthony Provenzano, Umang Swami, Jeffrey Weber, Krishna C Alluri, Sanjiv Agarwala, Paolo A Ascierto, Michael B Atkins, Nancy Davis, Marc S Ernstoff, Mark B Faries, Jason S Gold, Samantha Guild, David E Gyorki, Nikhil I Khushalani, Michael O Meyers, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K Sondak, Gilliosa Spurrier, Katy K Tsai, Alexander van Akkooi, Pauline Funchain
PURPOSE: To provide guidance to clinicians regarding the use of systemic therapy for melanoma. METHODS: ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS: A systematic review, one meta-analysis, and 34 additional randomized trials were identified. The published studies included a wide range of systemic therapies in cutaneous and noncutaneous melanoma. RECOMMENDATIONS: In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while either of those two agents or the combination of dabrafenib and trametinib should be offered in BRAF -mutant disease...
March 31, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#2
EDITORIAL
Lindsay M Morton
No abstract text is available yet for this article.
March 31, 2020: Journal of Clinical Oncology
#3
Raffit Hassan, George R Blumenschein, Kathleen N Moore, Alessandro D Santin, Hedy L Kindler, John J Nemunaitis, Shelly M Seward, Anish Thomas, Stella K Kim, Prabhu Rajagopalan, Annette O Walter, Dirk Laurent, Barrett H Childs, Nenad Sarapa, Cem Elbi, Johanna C Bendell
PURPOSE: This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody-drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with advanced, metastatic, or recurrent solid tumors known to express the tumor-differentiation antigen mesothelin. PATIENTS AND METHODS: This phase I, open-label, multicenter, dose-escalation and dose-expansion study of anetumab ravtansine enrolled 148 adult patients with multiple solid tumor types...
March 26, 2020: Journal of Clinical Oncology
#4
LETTER
Pirus Ghadjar, Dirk Böhmer, Stefan Höcht, Felix Sedlmayer, Thomas Wiegel
No abstract text is available yet for this article.
March 25, 2020: Journal of Clinical Oncology
#5
Monica M Bertagnolli, Brian Anderson, Kelly Norsworthy, Steven Piantadosi, Andre Quina, Richard L Schilsky, Robert S Miller, Sean Khozin
Wide adoption of electronic health records (EHRs) has raised the expectation that data obtained during routine clinical care, termed "real-world" data, will be accumulated across health care systems and analyzed on a large scale to produce improvements in patient outcomes and the use of health care resources. To facilitate a learning health system, EHRs must contain clinically meaningful structured data elements that can be readily exchanged, and the data must be of adequate quality to draw valid inferences...
March 25, 2020: Journal of Clinical Oncology
#6
Soumyajit Roy, Shawn Malone
No abstract text is available yet for this article.
March 25, 2020: Journal of Clinical Oncology
#7
Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie, Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki, Keita Uchino, Hirofumi Yasui, Hiroshi Tsukuda, Kazuhiro Nishikawa, Hiroyasu Ishida, Takeharu Yamanaka, Kentaro Yamazaki, Shuichi Hironaka, Taito Esaki, Narikazu Boku, Ichinosuke Hyodo, Kei Muro
PURPOSE: This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. PATIENTS AND METHODS: Patients with HER2-positive advanced G/GEJ cancer refractory to first-line chemotherapy with trastuzumab in combination with fluoropyrimidine and platinum were eligible. Patients were randomly assigned to the paclitaxel (80 mg/m2 , days 1, 8, and 15, every 4 weeks) or paclitaxel with trastuzumab (PT; initially 8 mg/kg followed by 6 mg/kg, every 3 weeks) arms...
March 24, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#8
William D Tap, Victor M Villalobos, Gregory M Cote, Howard Burris, Filip Janku, Olivier Mir, Murali Beeram, Andrew J Wagner, Liewen Jiang, Bin Wu, Sung Choe, Katharine Yen, Camelia Gliser, Bin Fan, Sam Agresta, Shuchi S Pandya, Jonathan C Trent
PURPOSE: Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists. Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a selective inhibitor of mutant IDH1 approved in the United States for specific cases of acute myeloid leukemia. We report outcomes of patients with advanced chondrosarcoma in an ongoing study exploring ivosidenib treatment...
March 24, 2020: Journal of Clinical Oncology
#9
Charles L Shapiro, Christina Lacchetti, Joan Neuner
No abstract text is available yet for this article.
March 24, 2020: Journal of Clinical Oncology
#10
LETTER
Elena Gonzalez-Rodriguez, Bérengère Aubry-Rozier, Delphine Stoll, Khalil Zaman, Olivier Lamy
No abstract text is available yet for this article.
March 24, 2020: Journal of Clinical Oncology
#11
Jennifer L Beebe-Dimmer, Ashley L Kapron, Alison M Fraser, Ken R Smith, Kathleen A Cooney
PURPOSE: Recently developed clinical guidelines suggest that men in families with specific cancer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setting of aggressive disease. However, although a family history (FH) of the same disease among close relatives is an established risk factor for prostate cancer (PC), a direct comparison of PC risk for men with each syndrome in a single population is needed. METHODS: The Utah Population Database was used to identify 619,630 men, age ≥ 40 years, who were members of a pedigree that included at least 3 consecutive generations...
March 24, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#12
Charlotte Demoor-Goldschmidt, Rodrigue S Allodji, Neige Journy, Carole Rubino, Wael Salem Zrafi, Ghazi Debiche, Damien Llanas, Cristina Veres, Cécile Thomas-Teinturier, Hélène Pacquement, Giao Vu-Bezin, Brice Fresneau, Delphine Berchery, Stephanie Bolle, Ibrahima Diallo, Nadia Haddy, Florent de Vathaire
PURPOSE: Between 10% and 20% of childhood cancer survivors (CCS) experience impaired growth, leading to small adult height (SAH). Our study aimed to quantify risk factors for SAH or growth hormone deficiency among CCS. METHODS: The French CCS Study holds data on 7,670 cancer survivors treated before 2001. We analyzed self-administered questionnaire data from 2,965 CCS with clinical, chemo/radiotherapy data from medical records. SAH was defined as an adult height ≤ 2 standard deviation scores of control values obtained from a French population health study...
March 20, 2020: Journal of Clinical Oncology
#13
Jakob Lauritsen, Mikkel Bandak, Michael Kreiberg, Thomas Wagner, Maria G G Kier, Christian Dehlendorff, Gedske Daugaard
No abstract text is available yet for this article.
March 18, 2020: Journal of Clinical Oncology
#14
LETTER
Suparna C Clasen, Chunkit Fung, Paul C Dinh, Lois B Travis
No abstract text is available yet for this article.
March 18, 2020: Journal of Clinical Oncology
#15
Jayesh Desai, Hui Gan, Catherine Barrow, Michael Jameson, Victoria Atkinson, Andrew Haydon, Michael Millward, Stephen Begbie, Michael Brown, Ben Markman, William Patterson, Andrew Hill, Lisa Horvath, Adnan Nagrial, Gary Richardson, Christopher Jackson, Michael Friedlander, Phillip Parente, Ben Tran, Lai Wang, Yunxin Chen, Zhiyu Tang, Wendy Huang, John Wu, Dewan Zeng, Lusong Luo, Benjamin Solomon
PURPOSE: Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E , wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib in patients with B-RAF - or K-RAS/N-RAS -mutated solid tumors. METHODS: During dose escalation, adult patients with histologically/cytologically confirmed advanced solid tumors received escalating doses of lifirafenib...
March 17, 2020: Journal of Clinical Oncology
#16
Jeong A Park, Nai-Kong V Cheung
Neuroblastoma (NB) is a malignant embryonal tumor of the sympathetic nervous system that is most commonly diagnosed in the abdomen, often presenting with signs and symptoms of metastatic spread. Three decades ago, high-risk NB metastatic to bone and bone marrow in children was not curable. Today, with multimodality treatment, 50% of these patients will survive, but most suffer from debilitating treatment-related complications. Novel targeted therapies to improve cure rates while minimizing toxicities are urgently needed...
March 13, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#17
Jean-François Delattre, Romain Cohen, Julie Henriques, Antoine Falcoz, Jean-François Emile, Serge Fratte, Benoist Chibaudel, Jérôme Dauba, Olivier Dupuis, Yves Bécouarn, Frédéric Bibeau, Julien Taieb, Christophe Louvet, Dewi Vernerey, Thierry André, Magali Svrcek
PATIENTS AND METHODS: A post hoc analysis of all pathologic reports from patients with stage III CC included in the IDEA France phase III study (ClinicalTrials.gov identifier: NCT00958737) investigating the duration of adjuvant fluorouracil, leucovorin, and oxaliplatin or capecitabine and oxaliplatin therapy (3 v 6 months) was performed. The primary objective was to determine the prognostic impact of TD on disease-free survival (DFS). The effect of the addition of TD to LNM count on pN restaging was also evaluated...
March 13, 2020: Journal of Clinical Oncology
#18
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Allen L Cohn, Margarita Romeo, Raquel Bratos, Marcia S Brose, Christopher DiSimone, Mark Messing, Daniel E Stepan, Corina E Dutcus, Jane Wu, Emmett V Schmidt, Robert Orlowski, Pallavi Sachdev, Robert Shumaker, Antonio Casado Herraez
PURPOSE: Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors. METHODS: Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORRWk24 ); secondary efficacy end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS)...
March 13, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#19
Andrea Maurichi, Rosalba Miceli, Hanna Eriksson, Julia Newton-Bishop, Jérémie Nsengimana, May Chan, Andrew J Hayes, Kara Heelan, David Adams, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Catherine Harwood, Daniele Bergamaschi, Dorothy Bennett, Konstantinos Lasithiotakis, Paola Ghiorzo, Bruna Dalmasso, Ausilia Manganoni, Francesca Consoli, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Vittoria Espeli, Cristina Mangas, Pietro Quaglino, Simone Ribero, Paolo Broganelli, Giovanni Pellacani, Caterina Longo, Corrado Del Forno, Lorenzo Borgognoni, Serena Sestini, Nicola Pimpinelli, Sara Fortunato, Alessandra Chiarugi, Paolo Nardini, Elena Morittu, Antonio Florita, Mara Cossa, Barbara Valeri, Massimo Milione, Giancarlo Pruneri, Odysseas Zoras, Andrea Anichini, Roberta Mortarini, Mario Santinami
PURPOSE: Thin melanomas (T1; ≤ 1 mm) constitute 70% of newly diagnosed cutaneous melanomas. Regional node metastasis determined by sentinel node biopsy (SNB) is an important prognostic factor for T1 melanoma. However, current melanoma guidelines do not provide clear indications on when to perform SNB in T1 disease and stress an individualized approach to SNB that considers all clinicopathologic risk factors. We aimed to identify determinants of sentinel node (SN) status for incorporation into an externally validated nomogram to better select patients with T1 disease for SNB...
March 13, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#20
Daniel V T Catenacci, Drew Rasco, Jeeyun Lee, Sun Young Rha, Keun-Wook Lee, Yung Jue Bang, Johanna Bendell, Peter Enzinger, Neyssa Marina, Hong Xiang, Wei Deng, Janine Powers, Zev A Wainberg
PURPOSE: To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA). PATIENTS AND METHODS: FPA144-001 was a phase I, open-label, multicenter trial consisting of the following 3 parts: part 1a involved dose escalation in patients with recurrent solid tumors at doses ranging from 0.3 to 15 mg/kg; part 1b involved dose escalation in patients with advanced-stage GEA; and part 2 involved dose expansion in patients with advanced-stage GEA that overexpressed FGFR2b at various levels (4 cohorts; high, medium, low, and no FGFR2b overexpression) and 1 cohort of patients with FGFR2b-overexpressing advanced-stage bladder cancer...
March 13, 2020: Journal of Clinical Oncology
Fetching more papers... 
